TAK Quote, Financials, Valuation and Earnings

HUTCHMED (China) has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of --. Takeda Pharmaceutical's return on equity of 4.01% beat HUTCHMED (China)'s return on equity of -5.49%.

Takeda Pharmaceutical has a consensus price target of $15.73, signalling upside risk potential of 19.62%. On the other hand HUTCHMED (China) has an analysts' consensus of $27.44 which suggests that it could grow by 73.53%. Given that HUTCHMED (China) has higher upside potential than Takeda Pharmaceutical, analysts believe HUTCHMED (China) is more attractive than Takeda Pharmaceutical.

Takeda Pharmaceutical has a beta of 0.504, which suggesting that the stock is 49.642% less volatile than S&P 500. In comparison HUTCHMED (China) has a beta of 0.808, suggesting its less volatile than the S&P 500 by 19.209%.

Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.65%. HUTCHMED (China) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. HUTCHMED (China) pays out -- of its earnings as a dividend.

Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than HUTCHMED (China) quarterly revenues of --. Takeda Pharmaceutical's net income of $619.7M is higher than HUTCHMED (China)'s net income of --. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 22.01x while HUTCHMED (China)'s PE ratio is 34.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.40x versus 6.56x for HUTCHMED (China). Usually stocks with elevated PS ratios are considered overvalued.

Healios KK has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of -107.23%. Takeda Pharmaceutical's return on equity of 4.01% beat Healios KK's return on equity of -137.21%.

Takeda Pharmaceutical has a consensus price target of $15.73, signalling upside risk potential of 19.62%. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Healios KK, analysts believe Takeda Pharmaceutical is more attractive than Healios KK.

Takeda Pharmaceutical has a beta of 0.504, which suggesting that the stock is 49.642% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.65%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.

Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than Healios KK quarterly revenues of $3.2M. Takeda Pharmaceutical's net income of $619.7M is higher than Healios KK's net income of -$3.4M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 22.01x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.40x versus 22.75x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of -5.57%. Takeda Pharmaceutical's return on equity of 4.01% beat PeptiDream's return on equity of 34.66%.

Takeda Pharmaceutical has a consensus price target of $15.73, signalling upside risk potential of 19.62%. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than PeptiDream, analysts believe Takeda Pharmaceutical is more attractive than PeptiDream.

Takeda Pharmaceutical has a beta of 0.504, which suggesting that the stock is 49.642% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.804, suggesting its less volatile than the S&P 500 by 19.554%.

Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.65%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.

Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than PeptiDream quarterly revenues of $36.8M. Takeda Pharmaceutical's net income of $619.7M is higher than PeptiDream's net income of -$2.1M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 22.01x while PeptiDream's PE ratio is 21.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.40x versus 7.43x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of 12.96%. Takeda Pharmaceutical's return on equity of 4.01% beat Nxera Pharma's return on equity of -5.58%.

Takeda Pharmaceutical has a consensus price target of $15.73, signalling upside risk potential of 19.62%. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Takeda Pharmaceutical is more attractive than Nxera Pharma.

Takeda Pharmaceutical has a beta of 0.504, which suggesting that the stock is 49.642% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.401, suggesting its less volatile than the S&P 500 by 59.86%.

Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.65%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.

Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than Nxera Pharma quarterly revenues of $62.4M. Takeda Pharmaceutical's net income of $619.7M is higher than Nxera Pharma's net income of $8.1M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 22.01x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.40x versus 2.95x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.